San
Francisco 9 May 2019 The Report Gaucher Disease Drugs Market Size, Share & Trends Analysis Report By Type, By
Therapy (Enzyme Replacement Therapy, Substrate Replacement Therapy), By Major
Markets, And Segment Forecasts, 2018 - 2025
The global gaucher disease (GD) drugs market size is expected to reach USD 1.71 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 1.1% during the forecast period. Growing prevalence of the disease and increasing research and development activities in the field are likely to help the market in gaining momentum over the coming years. With high unmet needs, there is a strong need for development of novel treatments with improved efficacy in neuronopathic complications, convenient dosage, and reduced cost.
Gaucher disease is a genetic metabolic
disorder, caused by mutations in GBA gene. People with Gaucher disease produce
low glucocerebrosidase (GCase), an enzyme required to degrade glucocerebroside.
Excess accumulation of lipids in spleen, liver, kidney, brain, lungs, and bone
marrow impedes the normal functioning of the organs.
In spite of being the most prevalent
lysosomal storage disorder, Gaucher disease is a rare condition with an average
prevalence of 1 in 100,000 individuals. However, certain ethnic races such as
Ashkenazi Jews are more susceptible to this disorder. Ashkenazi Jews have an
average disease prevalence of 1 in 500 individuals.
Currently, type 1 is the most common form
of Gaucher disease. This condition is nonneuronopathic in nature, as it does
not affect the central nervous system (CNS). Type 1 GD commanded more than
75.0% of the market in 2017. It is estimated to retain its position through
2025. Type 2 and type 3 are not as common as type 1.
On the basis of treatment, enzyme
replacement therapy (ERT) was the leading revenue contributor in the market in
2017. The growth of the segment can be attributed to strong sales of Cerezyme
and Vpriv. However, there has been an increase in inclination towards substrate
replacement therapy (SRT), spearheaded by Cerdelga and Zavesca. ERT is mostly
indicated for type 1 and type 3 (to address issues unrelated to the CNS), as
replacement enzymes cannot penetrate blood brain barrier. Additionally, there
is no effective treatment for type 2.
Access Research Report of Gaucher
Disease Drugs Market @ https://www.grandviewresearch.com/industry-analysis/gaucher-disease-drugs-market
Further key findings from the report suggest:
· Type 2 is the rarest of the three forms of
GD, with average mortality rate of less than two years
· Enzyme replacement therapy dominated the
treatment landscape, headed by Sanofi Genzyme’s Cerezyme. However, GD treatment
is witnessing a shift towards substrate replacement therapy, which is
anticipated to register a CAGR of over 7.5% during the forecast period
· The U.S. spearheaded the major markets, in
terms of sales as well as disease burden. The country will continue to dominate
the market through 2025, on account of widening patient base and easy
accessibility to treatments
· Some of prominent companies operating in
the market are Sanofi Genzyme, Shire, Pfizer, and Johnson & Johnson
· Sanofi Genzyme led the competitive space
and is projected to continue holding prominent position in the market over the
coming years, due to significant commercial performances of Cerezyme and
Cerdelga
Browse more reports of this category by Grand View
Research at: https://www.grandviewresearch.com/industry/pharmaceuticals
Grand View Research has
segmented the global Gaucher disease drugs market based on type, therapy, and
country:
Gaucher Disease Drugs Type Outlook
(Revenue, USD Million, 2017 - 2025)
·
Type 1
·
Type 2
·
Type 3
Gaucher Disease Drugs Therapy Outlook
(Revenue, USD Million, 2017 - 2025)
·
Enzyme Replacement Therapy
·
Substrate Replacement Therapy
Gaucher Disease Drugs Country Outlook
(Revenue, USD Million, 2017 - 2025)
·
U.S.
·
U.K.
·
Germany
·
Spain
·
France
·
Italy
·
Japan
Access Press Release of
Gaucher Disease Drugs Market@ https://www.grandviewresearch.com/press-release/global-gaucher-disease-drugs-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business decisions,
we offer market intelligence studies ensuring relevant and fact-based research
across a range of industries, from technology to chemicals, materials and
healthcare.
